JP Morgan Chase
RCUS icon

JP Morgan Chase’s Arcus Biosciences RCUS Stock Holding History

JP Morgan Chase’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$9.55K – 7802
2023
Q4 		$9.55K Sell
500
-1,700
-77% -$27.2K ﹤0.01% 6413
2023
Q3 		$39.5K Sell
2,200
-49,400
-96% -$993K ﹤0.01% 5869
2023
Q2 		$1.05M Buy
+51,600
New +$983K ﹤0.01% 4027
2021
Q3 		– Sell
-65,000
Closed -$1.78M – 6728
2021
Q2 		$1.78M Buy
+65,000
New +$1.86M ﹤0.01% 3876

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

JP Morgan Chase's RCUS Position: Q1 2026 in Review

JP Morgan Chase increased its Arcus Biosciences (RCUS) stake by 11% in Q1 2026, buying an estimated $174K and bringing the position to 80,817 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #4245.

JP Morgan Chase first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $13.8M in Q1 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • JP Morgan Chase held 80,817 shares of Arcus Biosciences worth $1.67M as of Q1 2026.
  • JP Morgan Chase bought 8,062 Arcus Biosciences shares in Q1 2026, an estimated $174K.
  • Arcus Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4245 holding.
  • JP Morgan Chase first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
  • JP Morgan Chase's Arcus Biosciences position peaked at $13.8M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.